Predictors of Treatment Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South Eastern Ethiopia

Demewoz Haile¹, Abulie Takele², Ketema Gashaw², Habtamu Demelash³, Dabere Nigatu²

1 School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia, 2 Department of Nursing, College of Medicine and Health Sciences, Madda Walabu University, Bale Goba, Ethiopia, 3 Department of Public Health, College of Medicine and Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia

* demewozhaile@yahoo.com

Abstract

Background

Treatment failure defined as progression of disease after initiation of ART or when the anti-HIV medications can't control the infection. One of the major concerns over the rapid scaling up of ART is the emergence and transmission of HIV drug resistant strains at the population level due to treatment failure. This could lead to the failure of basic ART programs. Thus this study aimed to investigate the predictors of treatment failure among adult ART clients in Bale Zone Hospitals, South east Ethiopia.

Methods

Retrospective cohort study was employed in four hospitals of Bale zone named Goba, Robe, Ginir and Delomena. A total of 4,809 adult ART clients were included in the analysis from these four hospitals. Adherence was measured by pill count method. The Kaplan Meier (KM) curve was used to describe the survival time of ART patients without treatment failure. Bivariate and multivariable Cox proportional hazards regression models were used for identifying associated factors of treatment failure.

Result

The incidence rate of treatment failure was found 9.38 (95% CI 7.79–11.30) per 1000 person years. Male ART clients were more likely to experience treatment failure as compared to females [AHR = 4.49; 95% CI: (2.61–7.73)]. Similarly, lower CD4 count (<100 m³/dl) at initiation of ART was found significantly associated with higher odds of treatment failure [AHR = 3.79; 95% CI: (2.46–5.84)]. Bedridden [AHR = 5.02; 95% CI: (1.98–12.73)] and ambulatory [AHR = 2.12; 95% CI: (1.08–4.07)] patients were more likely to experience treatment failure as compared to patients with working functional status. TB co-infected clients had also higher odds to experience treatment failure [AHR = 3.06; 95% CI: (1.72–
5.44]. Those patients who had developed TB after ART initiation had higher odds to experience treatment failure as compared to their counterparts [AHR = 4.35; 95% CI: (1.99–9.54]. Having other opportunistic infection during ART initiation was also associated with higher odds of experiencing treatment failure [AHR = 7.0, 95% CI: (3.19–15.37)]. Similarly having fair [AHR = 4.99 95% CI: (1.90–13.13)] and poor drug adherence [AHR = 2.56; 95% CI: (1.12–5.86)] were significantly associated with higher odds of treatment failure as compared to clients with good adherence.

**Conclusion**

The rate of treatment failure in Bale zone hospitals needs attention. Prevention and control of TB and other opportunistic infections, promotion of ART initiation at higher CD4 level, and better functional status, improving drug adherence are important interventions to reduce treatment failure among ART clients in Southeastern Ethiopia.

**Introduction**

Treatment failure can be defined as progression of disease after initiation of ART. Treatment failure happens when the anti-HIV medications can’t control the infection. Treatment failure might happen in the form of: virologic failure, immunologic failure, and clinical progression either in combination or discordantly [1]. People with HIV run a higher risk of virologic failure than previously thought, even when their number of Ribose Nucleic Acid (RNA) copies of the retrovirus per milliliter of blood is slightly above the detection threshold [2]. A 2012 WHO estimate showed that possible HIV drug resistance in African region is above 18%. Pooled estimates from eight African countries showed that the prevalence of HIV drug resistance among people experiencing first-line therapy failure at a median duration of 12 months was 62%(95% CI: 47–77) [3].

Treatment failure is associated with high risk of mortality among ART clients [4–6]. Patients who developed HIV drug resistance in the first year of treatment had higher risk of mortality [4]. Many studies showed evidence for an increased risk of progression to AIDS or death among those with poor immune recovery [7–9].

In resource poor setting like Ethiopia, ART treatment is not guided by viral load and genotypic testing at the start of treatment rather only by CD4 count and clinical progression. There are few studies in Ethiopia regarding the rate of treatment failure. A study conducted at Debre-markos Hospital, Northwest Ethiopia revealed that 21% of patients had developed immunologic failure with a failure rate of 8 per 100 patient-years of follow up [10]. Despite the few studies conducted in Ethiopia, the predictors of treatment failure among adult ART users are not well explored. Moreover the predictors of the treatment failure were not consistent across studies. Thus, this study aimed to identify the predictors of treatment failure among ART clients attending at Bale zone Hospitals. Identifying rate of treatment failure and associated factors would assist clinicians to provide targeted clinical and immune-based treatment approach. Additionally, this study would assist the effort to reduce high mortality among ART clients at the national level by improving the treatment success.
Methods

Ethical consideration

Ethical clearance was obtained from the Institutional Research Ethics Review Committee (IRERC) under the research and community service directorate office of Madda Walabu University. A letter of permission was obtained from zonal health department and finally willingness from each hospital was obtained to access the ART clients’ database. Only card number was used to identify cards and information collected from clients’ cards were kept anonymous and confidential.

Study setting, design and sampling procedure

Retrospective cohort study design was employed in four hospitals of Bale zone, Southeastern Ethiopia, named Goba hospital, Ginir hospital, Robe hospital and Delomena hospital. Goba hospital was the first hospital in Bale zone to initiate ART service at 2005/6. The ART service has further expanded later to other three hospitals such as Delomena, Ginir and Robe hospitals. Currently, there are 3197 ART clients in Goba hospital, 1381 ART clients in Robe hospital while there are 234 and 1464 clients in Delomena and Ginir hospitals, respectively. Totally 6276 HIV patients had been enrolled in the ART program [11]. This study was conducted on Adult (≥15 years old) ART users. The total numbers of ART clients included in this study were 4809. All adult ART clients who started treatment on these seven years between January 1, 2007 and December 31, 2014 were included in the study. The medical records of adult HIV patients (≥15 years) who initiated ART between 2007 and 2014 were included in the study. The schematic presentation of the sampling procedure is presented in Fig 1.

Data collection tool and quality control procedures

The federal ministry of health (FMOH) ART follow up form was used as a data extraction format. The data were extracted by the data clerk working at each hospital who took training for two days. Data extraction process was supervised by the principal investigators and trained supervisors. Data check was done on the collected data randomly by extracting the data of 2% patients from each hospital data base and compare with collected data by the data clerks. Totally, 368 ART clients’ data were checked against the data with the ART data base system by the principal investigators. The collected data were checked for completeness prior to data entry. Finally, data exploration on entered data was made to see unexpected values, outliers, and identify variables which need transformation.

Variables extracted and definitions

Socio-demographic characteristics (age, sex, educational status, marital status), duration on ART (measured in months), anthropometric measurements (weight in Kg and height in meter), WHO clinical staging (I-IV), CD4 count, functional status, presence of opportunistic infection including TB, drug regimen, presence of drug substitute, regimen change, regimen stopped presence of reported side effect and drug adherence were extracted from the data base.

Treatment duration for this study is the time of follow-up elapsed after ART initiation until the patient develops outcome of interest (treatment failure which was measured in months). The definition of each clinical stage was based on the WHO classification for AIDS clients according to AIDS related sign and symptoms the patient experiencing as stated in the national guideline [12]. Based on the Ethiopian ART guideline if an ART client had not seen for ≥ 1 month, the client considered as lost. However, if a client had not seen for ≥ 3 months, he/she would be recorded as a dropout. A client who is transferred to another health facility for care
was recorded in the database system as transferred out. For this study, any ART client who was recorded as lost to follow-up, transferred out or dropped-out was considered as censored. The functional status was categorized based on the definition stated on the ART follow up card. Working functional status clients were clients who are able to perform usual work in or out of the house while ambulatory functional status clients refer to clients who are able to perform activities of daily living. Bedridden functional status was designated to clients who are not able to perform activities of daily living. Adherence was measured based on the pills count when she/he comes for the follow up and recorded on the follow up forms either good, fair or poor. A patient was categorized as having good adherence if pill count or self reported adherence was greater than or equal to 95%. Fair adherence: if pill count or self reported adherence was less than 85%-95% while poor adherence: if pill count or self reported adherence was less than <85%.

Outcome measure

The treatment failure was classified retrospectively from what was reported by clinicians in patient’s clinical charts. A client was categorized treatment failure by a clinician as if he or she met one of the following three criteria after at least six months of follow up (1) a fall of CD4 count to pre-therapy baseline or below or 50% fall of absolute CD4 count from the on-treatment peak value (2) persistent CD4 levels below 100 cells/mm$^3$ (3) the occurrence or recurrence of HIV-related events after at least 3 months of treatment (clinical disease progression with development of an opportunistic infection) with the exception of immune reconstitution syndromes.

Statistical analysis

The statistical analysis was done by STATA version 12. Descriptive statistics such as frequency, median, inter-quartile range (IQR), mean and standard deviation ($\pm$SD) were computed for all continuous and categorical variables. Person time (years) contribution of each study
participant were calculated by comparing duration on ART and treatment failure as an outcome variable.

The Kaplan Meier (KM) curve with log rank test was used to describe the probability of survival without treatment failure. In order to identify the predictors of treatment failure, bivariate and multivariable Cox proportional hazards regression models were employed. The variables we chose for regression model as predictors were extracted from the ART data base. The reported predictors of treatment failure from literatures were not exactly the same, different literatures reported different predictors of treatment failure. Thus we have tested all the potential predictor variables extracted from the ART data base system in the regression.

Those statistically significant variables in bivariate analysis at p-value <0.25 [13] were entered into multivariable Cox proportional hazard regression model to identify the independent predictors of treatment failure. Both crude and adjusted hazard ratios (HRs) with 95% confidence intervals were reported and variables with p-values <0.05 in the multivariable Cox regression model were considered statistically significant factors of treatment failure.

Results

Characteristics of ART clients with treatment failure and success

This study included 4,809 adult ART clients from the four hospitals of Bale Zone. Majority of (57.64%) ART clients had attended their follow up at Goba Hospital. The median (IQR) age at ART initiation among adults cohorts was 33 years (IQR = 28–40). The highest proportion of treatment failure is found among ART clients attending in Delomena Hospital (6.47%) and among ART clients with age 45 years and above (5.24%). The prevalence of treatment failure among male ART clients was 4.37% while the prevalence of treatment failure was 0.72% among female ART clients. From ART clients with primary education level, the prevalence of treatment failure was found to be 2.91% while it was 2.74% among ART clients who had divorced from their partner (Table 1).

The descriptive statistics showed that about 4% of ART clients who had bedridden functional status at ART initiation experienced treatment failure while 2.29% ART clients who had ambulatory functional status at ART initiation experienced treatment failure.

None of ART clients with WHO clinical stage I at ART initiation experienced treatment failure. In contrary about 7% of ART clients with WHO clinical stage IV at ART initiation experienced treatment failure. The prevalence of treatment failure among ART clients who initiated ART at CD4 ≤ 200 per millimeter cube of blood was 2.51%. A total of 2.48% ART clients who had initiated ART at CD4 ≥ 300 per millimeter cube of blood experienced treatment failure. Among those who had TB—confection at ART initiation, nearly 4% had ART treatment failure while among ART clients who had developed TB after ART initiation, 7.77% of them had experienced treatment failure. Above 11% of ART clients with opportunistic infection at ART initiation had treatment failure. The proportion of ART clients with treatment failure among those who had normal BMI category were 3.17% (Table 2).

A total of 16.36% of ART clients with fair drug adherence at the first visit after ART initiation experienced treatment failure. However among those who had poor adherence at the first visit after ART initiation, below 2% of ART clients experienced treatment failure.

Among those ART clients who had drug regimen change experience, the prevalence of treatment failure was found 6.63% while the prevalence of treatment failure among those ART clients who had an experience of drug substitute was 4.17%. The highest prevalence of treatment failure was observed among ART clients who used 1d (AZT+3TC+EFV) (8.43%) regimen while the lowest prevalence of treatment failure was 1.53% among ART clients who were on 1e (TDF+3TC+EFV) drug regimen. The prevalence of treatment failure among those ART clients
who had reported drug side effect was found 2.88%. A total of 16.22% of treatment failure was occurred among ART clients who had reported fatigue as a drug side effect (Table 3).

### Treatment failure

In this ART cohort, there were 113 treatment failures in 11,830 person years of retrospective follow up. This makes the incidence rate of treatment failure 9.38 (95% CI: 7.79–11.30) per 1000 person years. As shown in Fig 2, the treatment failure occurred before 10 months of duration on ART. The highest rate of treatment failure was occurred between 6 months and 10 months of ART initiation (Fig 2).

### Predictors of treatment failure

The multivariable Cox proportional hazards regression analysis showed that older age clients, male ART clients, bedridden clients, ambulatory clients, TB co-infected clients at ART initiation, clients who develop TB co-infection after ART initiation, type of drug regimen used, drug adherence, clients with low CD4 count, and clients who had developed other opportunistic infection had a statistically significant association with treatment failure among ART clients. Male ART clients were 4.49 times more likely to experience treatment failure as compared to females ART clients \([\text{AHR} = 4.49; 95\% \text{ CI: (2.61–7.73)}]\). The multivariable model showed the estimated risk of treatment failure increases 2.91 times if the ART client is a year older \([\text{AHR} = 2.91; 95\% \text{ CI: (2.82–2.97)}]\). Similarly, lower CD4 count at initiation of ART was found significantly associated with higher odds of treatment failure \([\text{AHR} = 3.79; 95\% \text{ CI: (2.46–}}]\

### Table 1. Socio-demographic characteristics of HIV patients who had ART treatment failures and success in Bale Zone hospitals, South East Ethiopia; 2015.

| Variables                  | Treatment failure | Treatment successful |
|----------------------------|-------------------|----------------------|
|                            | Number            | Percent              | Number            | Percent              |
| **Hospitals**              |                   |                      |                   |                     |
| Goba                       | 71                | 2.56                 | 2,701             | 97.44                |
| Robe                       | 6                 | 0.59                 | 1,003             | 99.41                |
| Delomena                   | 9                 | 6.47                 | 130               | 93.53                |
| Ginnir                     | 27                | 3.04                 | 862               | 96.96                |
| **Age (years)**            |                   |                      |                   |                     |
| 15–24                      | 0                 | 0                    | 606               | 100                  |
| 25–34                      | 31                | 1.60                 | 1,912             | 98.40                |
| 35–44                      | 37                | 2.64                 | 1,365             | 97.36                |
| ≥ 45                       | 45                | 5.24                 | 813               | 94.76                |
| **Sex of participants**    |                   |                      |                   |                     |
| Male                       | 94                | 4.37                 | 2,059             | 95.63                |
| Female                     | 19                | 0.72                 | 2,637             | 99.28                |
| **Educational level**      |                   |                      |                   |                     |
| No Education               | 13                | 1.17                 | 1,100             | 98.83                |
| Primary                    | 54                | 2.91                 | 1,800             | 97.09                |
| Secondary and above        | 46                | 2.72                 | 1,648             | 97.28                |
| **Marital status**         |                   |                      |                   |                     |
| Never married              | 14                | 2.41                 | 566               | 97.59                |
| Married                    | 75                | 2.50                 | 2,931             | 97.50                |
| Divorced                   | 19                | 2.74                 | 675               | 97.26                |
| Widowed                    | 5                 | 1.23                 | 403               | 98.77                |

doi:10.1371/journal.pone.0164299.t001
Bedridden patients were 5.02 times more likely to experience treatment failure as compared to patients with working functional status [AHR = 5.02; 95% CI: (1.98–12.73)]. Those ART clients with ambulatory functional status were 2.12 times more likely to experience treatment failure as compared to clients with working functional status [AHR = 2.12; 95% CI: (1.08–4.07)]. TB co-infected clients were 3.06 times more likely to experience treatment failure [AHR = 3.06; 95% CI: (1.72–5.44)]. Those ART clients who had developed TB after ART initiation had higher odds to experience treatment failure as compared to their counterparts [AHR = 4.35; 95% CI: (1.99–9.54)].

ART clients who had other opportunistic infection during ART initiation were 7 times more likely to experience treatment failure [AHR = 7.0; 95% CI: (3.19–15.37)]. Similarly having fair drug adherence was significantly associated with higher odds of treatment failure [AHR = 4.99 95% CI: (1.90–13.13)]. ART clients with poor drug adherence had higher odds to experience treatment failure as compared to clients with good adherence [AHR = 2.56; 95% CI: (1.12–5.86)]. ART clients who had used regimen 1b(d4T+3TC+EFV) [AHR = 0.29; 95% CI: (0.12–0.69)] and 1c(AZT+3TC+NVP) [AHR = 0.45; 95% CI: (0.22–0.89)] had lower odds of experiencing treatment failure as compared to clients who had used regimen 1a(d4T+3TC+NVP). However, ART clients who had used regimen 1d(AZT+3TC+EFV) [AHR = 4.47; 95% CI: (1.99–9.54)] had higher odds of treatment failure.

### Table 2. Clinical characteristics of HIV patients who had ART treatment failures and success in Bale Zone hospitals, South East Ethiopia; 2015.

| Variables                        | Treatment failure | Treatment successful |
|----------------------------------|-------------------|----------------------|
| **Baseline* functional status**  |                   |                      |
| Working                          | 85                | 2.25                 | 3,686 | 97.75  |
| Ambulatory                       | 18                | 2.29                 | 768   | 97.71  |
| Bedridden                        | 10                | 4.02                 | 239   | 95.98  |
| **WHO stage at baseline**        |                   |                      |
| WHO Stage 1                      | 0                 | 0                    | 683   | 100    |
| WHO stage 2                      | 16                | 1.82                 | 865   | 98.18  |
| WHO stage 3                      | 70                | 2.44                 | 2,800 | 97.56  |
| WHO stage 4                      | 27                | 7.20                 | 348   | 92.80  |
| **Initial CD4 Count**            |                   |                      |
| ≤200                             | 72                | 2.51                 | 2,800 | 97.49  |
| 201–300                          | 14                | 1.61                 | 854   | 98.39  |
| >300                             | 16                | 2.48                 | 628   | 97.52  |
| **TB co-infection at initiation of ART** |       |                      |
| Positive                         | 21                | 3.95                 | 510   | 96.05  |
| Negative                         | 92                | 2.15                 | 4,186 | 97.85  |
| **Patient develop TB after ART initiation** |       |                      |
| Yes                              | 8                 | 7.77                 | 95    | 92.23  |
| No                               | 105               | 2.23                 | 4,601 | 97.77  |
| **Presence of other opportunistic infection** |       |                      |
| Yes                              | 9                 | 11.54                | 69    | 88.46  |
| No                               | 104               | 2.20                 | 4,627 | 97.80  |
| **BMI at Initial visit**         |                   |                      |
| <18.5                            | 36                | 1.81                 | 1,958 | 98.19  |
| 18.5–24.9                        | 76                | 3.17                 | 2,321 | 96.83  |
| ≥25.0                            | 1                 | 0.33                 | 302   | 99.67  |

doi:10.1371/journal.pone.0164299.t002
CI: (1.81–11.04)] had higher odds of experiencing treatment failure as compared to clients who had used regimen 1a (d4T+3TC+NVP) (Table 4).

Discussion

This study found 113 treatment failures per 11830 person years of observation among ART clients making the overall incidence rate of 9.38 (95% CI: 7.79–11.30) per 1000 person years. This incidence rate is relatively low as compared to the incidence rate reported by different studies in Ethiopia and abroad [10, 14, 15]. A study from Mozambique reported that rate of immunologic failure was 17.2 (95% CI: 12.6–22.9) per 100 person-years of follow-up [16]. Another study from Thailand showed that 4.3%, 10.7%, and 4.9% met the criteria of virological failure, immunological failure, and clinical failure, respectively. The probable justification could the difference in ART initiation criteria, nutritional factor and follow up approach between Ethiopia and those countries. A relatively similar incidence rate of treatment failure was reported from Ghana [17]. A study from Debremarks Hospital, Northwest Ethiopia revealed that the rate of immunological failure was 8 per 100 person-years of follow up [10].
This study found that the highest rate of treatment failure was occurred between 6 months and 10 months of ART initiation. Studies agreed that most of the treatment failure are occurred during early days of the ART initiation [14, 18]. The test for trend over time showed a decrease in the rate of immunological failure with each additional year since the initial immunological success [14]. Treatment failure that occurred within the first early months of therapy might be resulted from poor adherence, poor status disclosure, severe drug toxicity and regimen changes [19]. Promoting early disclosure of ART status, counseling on the adherence of drugs, appointing clients more frequently to visit the clinic and linking ART clients with the community health workers during early phases of treatment might be important to reduce the incidence of treatment failure in the first 12 months of ART initiation. One of the factors found to be associated with treatment failure was gender. Male ART clients were more likely to experience treatment failure compared to female ART clients. A similar finding was reported by studies from two African countries which showed that men on ART were more vulnerable to virologic failure than women [20, 21]. There have been many studies which showed that mortality among male ART clients was significantly higher as compared to their female counter parts [22–30]. One of the possible reasons could be the difference in mean CD4 count between male and female during ART initiation. Furthermore studies showed that males had unhealthy behaviors like using alcohol, cigarette, Khat etc than females [31–35] which might lead them to poor drug adherence and reduce the overall treatment success. Another study revealed that intravenous drug users were at higher odds to experience treatment failure as compared to their counterparts [14].

A retrospective case control study in India identified older age as a factor for treatment failure [36]. This finding showed that increasing age is associated with increased odds of treatment failure. Similarly, it was found that those bedridden and ambulatory clients were more likely to experience treatment failure compared to working clients at their ART initiation period. In this regard, a study from Ethiopia reported supporting evidences that inability to work due to health problem is associated with treatment failure [10]. The high prevalence of mortality among ART clients with poor baseline functional performance might be due to the treatment failure as evidenced in this study [28, 37, 38]. Lower baseline CD4 count was significantly associated with higher odds of treatment failure. There are studies which showed that lower baseline CD4 count especially less than 100m$^3$/dl was associated with higher odds of treatment failure [39, 40].
Table 4. Bivariate and multivariable cox regression model on factors associated with treatment failure among ART clients in South-eastern Ethiopia, 2015.

| Variables                  | Treatment failure as an outcome                      | @Unadjusted Hazard Ratio (95% CI) | *Adjusted Hazard Ratio (95% CI) |
|----------------------------|-------------------------------------------------------|----------------------------------|---------------------------------|
| Age of the ART client      |                                                       | 2.89(2.86–2.92)                  | 2.91(2.82–2.97)                 |
| Sex                        |                                                       |                                  |                                 |
| Male                       |                                                       | 1.21 (1.14–1.28)                 | 4.49 (2.61–7.73)                |
| Female                     | Reference                                             | Reference                        | Reference                       |
| Marital status             |                                                       |                                  |                                 |
| Never married              | Reference                                             |                                  |                                 |
| Married                    | 0.94(0.86–1.03)                                       | 0.97(0.37–2.48)                  |                                 |
| Widowed                    | 0.89(0.79–0.99)                                       | 1.88(0.67–5.30)                  |                                 |
| Divorced                   | 0.88(0.78–1.00)                                       | 1.41(0.29–6.99)                  |                                 |
| Functional status          |                                                       |                                  |                                 |
| Working                    | Reference                                             |                                  |                                 |
| Ambulatory                 | 1.0(0.92–1.08)                                        | 2.12 (1.08–4.07)                 |                                 |
| Bedridden                  | 1.97(1.03–3.81)                                       | 5.02 (1.98–12.73)                |                                 |
| Baseline WHO stage         |                                                       |                                  |                                 |
| WHO Stage 1                | Reference                                             |                                  |                                 |
| WHO Stage 2                | 0.89(0.37–2.16)                                       | 0.91(0.82–1.02)                  |                                 |
| WHO stage 3                | 1.38 (0.674–2.83)                                     | 0.95 (0.86–1.04)                 |                                 |
| WHO stage 4                | 4.11(1.82–9.31)                                       | 0.86(0.75–1.003)                 |                                 |
| CD4 Count at ART initiation|                                                       |                                  |                                 |
| < 100 m³/dl                | 3.08(2.12–4.47)                                       | 3.79 (2.46–5.84)                 |                                 |
| ≥100 m³/dl                 | Reference                                             | Reference                        |                                 |
| TB co-infection            |                                                       |                                  |                                 |
| Positive                   | 2.42(1.51–3.89)                                       | 3.06 (1.72–5.44)                 |                                 |
| Negative                   | Reference                                             | Reference                        |                                 |
| Developing TB after ART initiation |                                 |                                  |                                 |
| Yes                        | 3.86(1.87–7.95)                                       | 4.35(1.99–9.54)                  |                                 |
| No                         | Reference                                             | Reference                        |                                 |
| Other opportunistic infection at ART initiation |                                 |                                  |                                 |
| Yes                        | 7.53(3.81–14.90)                                      | 7.0(3.19–15.37)                  |                                 |
| No                         | Reference                                             | Reference                        |                                 |
| Baseline BMI (kg/m²)       |                                                       |                                  |                                 |
| <18.5                      | 1.72 (1.161–2.57)                                     | 1.5(0.95–2.35)                   |                                 |
| 18.5–24.99                 | Reference                                             | Reference                        |                                 |
| ≥25.0                      | 0.201 (0.03–1.47)                                     | 0.18(0.03–1.37)                  |                                 |
| Adherence at first visit after ART initiation |                                 |                                  |                                 |
| Good                       | Reference                                             | Reference                        |                                 |
| Fair                       | 7.52(3.77–14.99)                                      | 4.99(1.90–13.13)                 |                                 |
| Poor                       | 1.54(0.71–3.34)                                       | 2.56(1.12–5.86)                  |                                 |
| Type of ARV regimen        |                                                       |                                  |                                 |
| 1a(d4T+3TC+NVP)             | Reference                                             | Reference                        |                                 |
| 1b(d4T+3TC+EFV)             | 1.15(0.61–2.18)                                       | 0.29(0.12–0.69)                  |                                 |
| 1c(AZT+3TC+NVP)             | 0.82(0.48–1.41)                                       | 0.45(0.22–0.89)                  |                                 |
| 1d(AZT+3TC+EFV)             | 4.19(1.89–9.28)                                       | 4.47(1.81–11.04)                 |                                 |
| 1e(TDF+3TC+EFV)             | 1.20(0.651–2.20)                                      | 1.14(0.59–2.20)                  |                                 |
TB co-infection is one of the most consistent predictor for treatment failure among ART patients. This study also found that those ART clients who had TB co-infection during ART initiation were 3 fold higher to experience treatment failure as compared to their counterparts. Studies from Ethiopia and abroad reported similar finding which underline the importance of TB in treatment success [10, 36]. Not only co-infection during ART initiation but also developing TB after ART initiation was one of the significant factors associated with treatment failure. Similarly, having other opportunistic infection during ART initiation was significantly associated with treatment failure. Consistent finding was also reported from Debremarkos Hospital which revealed that having pneumonia was significantly associated with higher odds of having treatment failure [10].

This study found that poor drug adherence was associated with higher odds of having treatment failure. A consistent finding was reported from Tanzania which showed that history of poor antiretroviral therapy adherence due to exposure to drug holiday was associated with treatment failure [15]. Another study from Kenya showed that imperfect ART adherence as associated factor for treatment failure [41]. A study from Ethiopia reported that treatment interruption associated with higher odds of treatment failure [10].

In this study it was found that there is variation in the experience of treatment failure among drug regimens. Those patients who had used 1f (d4T+3TC+EFV) and 1c (AZT+3TC+NVP) had lower odds of treatment failure as compared to 1a (d4T+3TC+NVP) patients. On the other hand those patients who had used 1d (AZT+3TC+EFV) drug regimen had higher odds to experience treatment failure as compared to 1a based treatment regimen. A case control study from Kenya revealed that those ART clients who were on Zidovudine based ART regimen experienced treatment failure as compared to other regimen based treatments [41].

**Limitations of the study**

This study has some limitations. The first limitation was that this study conducted based on secondary data analysis which missed key variables those should be considered. The other limitation was in this study, clinical failure and immunological failure were used for measuring treatment failure which usually underestimate the treatment failure. Though the study used clinical failure and immunological failure to determine the rate of treatment failure, we could not present the figures of treatment failure by type as immunological failure and clinical failure separately due to the fact that the treatment failure is not presented separately by type in the database system for all patients. The gold standard method for measuring treatment failure is the virological assessment however, which was not used in this study. Incomplete data was also one of the major limitations of this study.

**Conclusion**

The rate of treatment failure needs attention in the Bale zone Hospitals. The highest rate of treatment failure was occurred between 6 months and 10 months of ART initiation. Factors
associated with treatment failure were age of clients, male ART clients, bedridden clients, ambulatory clients, TB co-infected clients at ART initiation, clients who develop TB co-infection after ART initiation, type of drug regimen used, drug adherence, clients with low CD4 count at ART initiation, and clients who have reported other opportunistic infection. Those factors should be considered in prevention of treatment failure among ART clients. Continual follow up and focused care especially in the first 12 months of ART initiation is important to identify early treatment failure using the available resources.

Supporting Information

S1 File. Data set from which this manuscript produced.

Acknowledgments

We would like to acknowledge Madda Walabu University for financing this study.

Author Contributions

Conceptualization: DH AT KG HD DN.

Formal analysis: DH AT KG HD DN.

Funding acquisition: DH AT DN.

Investigation: DH AT KG HD DN.

Methodology: DH AT DN.

Project administration: DH AT DN.

Resources: DH AT DN.

Supervision: DH AT DN.

Validation: DH AT DN.

Visualization: DH AT KG HD DN.

Writing – original draft: DH AT KG HD DN.

Writing – review & editing: DH AT KG HD DN.

References

1. Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009; 4:456–66. doi: 10.1097/COH.0b013e328331dea5 PMID: 20048711

2. Laprise C, Pokomandy Ad, Baril J.-G., Dufresne S, Trottier H. Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation. Clinical Infectious Diseases. 2013; 57(10): 1489. doi: 10.1093/cid/cit529 PMID: 23946221

3. WHO. HIV drug resistance report 2012.

4. Liao L, Xing H, Su B, Wang Z, Ruan Y, Wang X, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS. 2013; 27:1815–24. doi: 10.1097/QAD.0b013e3283611931 PMID: 23803794

5. Cozzi-Lepri A, Phillips AN, Ciotet B, Mocroft A, Ruiz L, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS. 2008; 22:2187–98. doi: 10.1097/QAD.0b013e328251e04f PMID: 18832882
6. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America Clinical Infectious Diseases. 2009; 49:1582–90.

7. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infectious Diseases. 2006; 6:59. doi: 10.1186/1471-2334-6-59 PMID: 16551345

8. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kene MDK. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. Journal of Infectious Disease. 2001; 183:1328–35. doi: 10.1086/319861 PMID: 11294663

9. Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. Journal of the International AIDS Society. 2014; 17:18651. doi: 10.7448/IAS.17.1.18651 PMID: 24594114

10. Melsew YA, Terefe MW, Tessema GA, Ayele TA. Rate of Immunological Failure and its Predictors among Patients on Highly Active Antiretroviral Therapy at Debremekros Hospital, Northwest Ethiopia: A Retrospective Follow up Study. AIDS & Clinical Research. 2013; 4:211.

11. Bale zone Health Office. Annual report on the Antiretroviral report in Bale zone, Oromiya Region 2013.

12. Federal Ministry of Health. National Guidelines for Antiretroviral Treatment in Ethiopia. Addis Ababa: FHAPCO. 2007.

13. Peter C, Jack V. Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. Journal of Clinical Epidemiology. 2004; 57:1138–46. doi: 10.1016/j.jclinepi.2004.04.003 PMID: 15567629

14. Dragsted UB, Mocroft A, Vella S, Viard J-P, Hansen A-BE, Panos G, et al. Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV-1–Infected Adults: A EuroSIDA Study. The Journal of Infectious Diseases. 2004; 190:148–55. doi: 10.1086/420786 PMID: 15195254

15. Kapesa A, Magesa D, William A, Kaswija J, Seni J, Makwaya C. Determinants of immunological failure among clients on the first line treatment with highly active antiretroviral drugs in Dar es Salaam, Tanzania Asian Pacific Journal of Tropical Biomedicine. 2014; 4(2):S620–S4. doi: 10.12980/APJTB.4.2014APJT B-2014APJT B-0035

16. Palladino C, Briz Vn, Bello’n JMa, Ba’rtolo I, Carvalho Pc, Camacho R, et al. Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Health-care Settings in Mozambique. PLoS ONE. 2013; 8(12):e82718. doi: 10.1371/journal.pone.0082718 PMID: 24376569

17. Amenyah R, Nagai H, Torpey K, Rahman Y, Aryee D, Mukadi YD, et al. Characteristics of patients failing antiretroviral treatment in Ghana. XVI International AIDS Conference Abstract no CDB1117. 2006

18. Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infectious Diseases. 2014; 14:28. doi: 10.1186/1471-2334-14-28 PMID: 24422906

19. Workneh N, Girma T, Wolde M. Immunologic and clinical outcomes of children on HAART: a Retrospective cohort analysis at Jimma University specialized hospital. Ethiopian Health Sci. 2009; 19(2):75–82. doi: 10.4314/ehs.v19i2.69422

20. Kipp W, Alibhai A, Saunders LD, Senthilselvan A, Kaler A, Konde-Lule J, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care. 2010; 22(3):271–8. doi: 10.1080/09540120903193625 PMID: 20390506

21. Penot P, Héma A, Bado G, Kaboré F, Soré I, Sombié D, et al. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso. J Int AIDS Soc. 2014; 17 (1):18646. doi: 10.7448/IAS.17.1.18646 PMID: 24433983

22. Tsegaye E, Worku A. Assessment of antiretroviral treatment outcome in public hospitals, South Nations Nationalities and Peoples Region, Ethiopia. Ethiopian Journal of Health Development 2011; 25(2).

23. Barbara A, Levin J, Birunghi J, Namara G, Coutinho A, Grosskurth H. Mortality in an antiretroviral therapy programme in Jinja, South-east Uganda: a prospective cohort study. AIDS Research and Therapy. 2011; 8(39). doi: 10.1186/1742-6405-8-39 PMID: 22018262

24. Bajunirwe F, Arts E, Tisch D, Debanne S, Sethi A. Survival, adherence to care and antiretroviral treatment (ART) among HIV-infected adults in rural Western Uganda. Abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007. International AIDS Society [abstract WEPEB049]. Sydney, Australia: 2007.
25. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008; 22(1897–1908). doi: 10.1097/QAD.0b013e32830007cd PMID: 18784453

26. Mageda K, Leyna GH, Mmbaga EJ. High Initial HIV/AIDS-Related Mortality and -Its Predictors among Patients on Antiretroviral Therapy in the Kagera Region of Tanzania: A Five-Year Retrospective Cohort Study. AIDS Research and Treatment. 2012; http://dx.doi.org/10.1155/2012/843598. PMID: 22973505

27. Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupta N, Bisson GP, et al. Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in Low- and Middle-Income Countries (LMIC): A Systematic Review and Meta-Analysis. PLoS ONE. 2011; 6(12):e28691. doi: 10.1371/journal.pone.0028691 PMID: 24369908

28. Poka-Mayap V, Pefura-Yone EW, Kengne AP, Kuaban C. Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study in far-western Region, 2006–2011. BMC Infectious Diseases. 2013; 13(604). doi: 10.1186/bmjoenp-2013-003210 PMID: 23852140

29. Bhatta L, Klouman E, Deuba K, Shrestha R, Karthikeyan S, Ekstrom AM, et al. Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in far-western Region, 2006–2011. BMC Infectious Diseases. 2013; 13(604). doi: 10.1186/bmjoenp-2013-003210 PMID: 21614882

30. Taylor-Smith K, Tweya H, Harries A, Souttoune E, John A. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Medical Journal. 2010; 22(2):49–56. doi: 10.4314/mmj.v22i2.57 PMID: 21614882

31. Hymowitz N, Cummins KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tobacco Control. 1997; 6(2):s57–s62. doi: 10.1136/tc.6.suppl_2.S57 PMID: 9583654

32. Steyn K, Bradshaw D, Norman R, Laubscher R, Saloojee Y. Tobacco use in South Africans during 1998: the first demographic and health survey. J Cardiovasc Risk. 2002; 9:161–70. doi: 10.1177/174182670200900305 PMID: 12202839

33. Jagoee K, Edwards R, Mugusi F, Whiting D, Unwin N. Tobacco smoking in Tanzania, East Africa: population based smoking prevalence using expired alveolar carbon monoxide validation tool. Tobacco Control. 2002; 11:210–4. doi: 10.1136/tc.11.3.210 PMID: 12198270

34. Rudatsikira E, Dondog J, Sziya S, Muula AS. Prevalence and determinants of adolescent cigarette smoking in Mongolia. Singapore Med Journal. 2008; 49(1):57–62. PMID: 18204771

35. Reda AA, Moges A, Yazew B, Biadgilign S. Determinants of cigarette smoking among school adolescents in eastern Ethiopia: a cross-sectional study. Harm Reduction Journal. 2012; 9:39. doi: 10.1186/1477-7517-9-39 PMID: 22272891

36. Singh A, Agarwal A, Chakravarty J, Kumar S, Rai M, Sundar S. Predictive Markers of Failure of First Line Anti Retroviral Treatment in HIV Patients in India. Journal of AIDS and Clinical Research. 2013; 4:210. doi: 10.4172/2155-6113.1000210

37. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. AIDS Research and Therapy. 2012; 9(15). doi: 10.1186/1742-6405-9-15 PMID: 22906851

38. Abebe N, Alemu K, Asfaw T, Abajobir AA. Survival status of HIV positive adults on antiretroviral treatment in Debre Markos Referral Hospital, Northwest Ethiopia: a retrospective cohort study. The Pan African Medical Journal. 2014; 17:88. doi: 10.11604/pamj.2014.17.88.3262 PMID: 25452834

39. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008 22(17):2291–302. doi: 10.1097/QAD.0b013e32832121ca8 PMID: 18981768

40. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infectious Diseases. 2012; 12:197. doi: 10.1186/1471-2334-12-197 PMID: 22916836

41. Kwobah CM, Mwangi AW, Koech JK, Simiyu GN, Siika AM. Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study. World Journal of AIDS. 2012; 2:271–8. doi: 10.4236/wja.2012.24036